RaQualia Pharma Inc. (JP:4579)
:4579
Want to see JP:4579 full AI Analyst Report?
4579 Stock Chart & Stats
¥1010.00
-¥6.00(-1.49%)
At close: 4:00 PM EST
¥1010.00
-¥6.00(-1.49%)
Day’s Range― - ―
52-Week Range¥406.00 - ¥1,465.00
Previous CloseN/A
Volume117.60K
Average Volume (3M)352.93K
Market Cap
¥19.42B
Enterprise Value¥19.08B
Total Cash (Recent Filing)¥3.24B
Total Debt (Recent Filing)¥2.90B
Price to Earnings (P/E)87.6
Beta0.96
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.56
Shares Outstanding24,458,673
10 Day Avg. Volume795,170
30 Day Avg. Volume352,926
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)3.47
Price to Sales (P/S)6.01
P/FCF Ratio-56.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)48.4
Revenue Forecast (FY)¥4.59B
Bulls Say, Bears Say
Bulls Say
Gross Margins & ProfitabilitySustained very high gross margins (80–92%) provide structural margin protection for the business model, enabling operating leverage as revenue scales. The 2025 return to positive EBIT and net income indicates core R&D outputs can translate to profitable results when paired with licensing/partner deals, supporting long-term margin sustainability even if SG&A or development spend varies.
Revenue Growth TrendA ~31% revenue acceleration in 2025 signals durable progress in monetizing the pipeline and greater commercial traction with partners. Persistent top-line growth improves negotiating leverage for future partnerships and milestone receipts, increases scale benefits across fixed R&D costs, and supports reinvestment into discovery and clinical development over the coming months.
Partnership-led Business ModelA partnership/out‑licensing model transfers late‑stage development and commercialization risk to partners while providing upfronts, milestones, and royalties. This model conserves capital, accelerates monetization of discovery successes, and leverages the firm's R&D expertise — a durable structural advantage for a small, discovery-focused biotech.
Bears Say
Weak Cash GenerationNegative operating and free cash flow in 2025 indicate the company is not converting accounting profits into reliable cash, requiring external financing or milestone-dependent receipts to fund operations. Persistent or episodic negative cash flow increases dilution and constrains the ability to advance multiple programs concurrently over the medium term.
Earnings Volatility & Low ROEA history of large losses interspersed with profitable years and a low ROE (~4%) points to inconsistent capital efficiency. This volatility reduces predictability for partners and investors, complicates long-term planning, and suggests the company has struggled to reliably translate R&D investment into sustained shareholder returns.
Lumpy, Milestone‑driven RevenueDependence on upfronts and milestone payments creates inherently lumpy and timing‑uncertain revenue streams. Without diversified product sales or predictable royalties, cash flow and financial planning hinge on discrete events, raising structural variability in funding needs and execution risk across the 2–6 month horizon and beyond.
RaQualia Pharma Inc. News
4579 FAQ
What was RaQualia Pharma Inc.’s price range in the past 12 months?
RaQualia Pharma Inc. lowest stock price was ¥406.00 and its highest was ¥1465.00 in the past 12 months.
What is RaQualia Pharma Inc.’s market cap?
RaQualia Pharma Inc.’s market cap is ¥19.42B.
When is RaQualia Pharma Inc.’s upcoming earnings report date?
RaQualia Pharma Inc.’s upcoming earnings report date is May 15, 2026 which is in 10 days.
How were RaQualia Pharma Inc.’s earnings last quarter?
RaQualia Pharma Inc. released its earnings results on Feb 13, 2026. The company reported ¥35.82 earnings per share for the quarter, beating the consensus estimate of N/A by ¥35.82.
Is RaQualia Pharma Inc. overvalued?
According to Wall Street analysts RaQualia Pharma Inc.’s price is currently Overvalued.
Does RaQualia Pharma Inc. pay dividends?
RaQualia Pharma Inc. does not currently pay dividends.
What is RaQualia Pharma Inc.’s EPS estimate?
RaQualia Pharma Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RaQualia Pharma Inc. have?
RaQualia Pharma Inc. has 24,458,673 shares outstanding.
What happened to RaQualia Pharma Inc.’s price movement after its last earnings report?
RaQualia Pharma Inc. reported an EPS of ¥35.82 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.207%.
Which hedge fund is a major shareholder of RaQualia Pharma Inc.?
Currently, no hedge funds are holding shares in JP:4579
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaQualia Pharma Inc.
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.